Skip Ribbon Commands
Skip to main content



Primary Diagnosis

Atrial Fibrillation (AFib)

​Study Purpose

A randomized (Double Blind/Double Dummy) clinical trial to test if treatment with apixaban, compared with aspirin, will reduce the risk of stroke and systemic embolism in patients with device detected subclinical Atrial Fibrillation.

Principal Investigator: Hafiza Khan, MD

​Trial Details

Locations: Arrhythmia Management

Sponsor: Hamilton Health Sciences through the Population Health Research Institute

IRB Number: 017-386

Trial Status: Enrolling

Exclusions: Adults only

Change in Care: Follow up every 6 months to refill study drug

Contact Information:

Melissa Johnson

Destiny Barnett

Full Protocol Title

Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA)

Get Detailed I​nf​ormation On »​​​​​​​​​​​​​​​​​​​​​